Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer: An Open-label, Randomized, Cross-Over Trial.
Sponsor: Chinese University of Hong Kong
Terminated
Endpoint reached
Other terminated trials from Chinese University of Hong Kong
Other Prostate Cancer trials with similar outcome
Listed as NCT04409288, this PHASE3 trial focuses on Prostate Cancer and remains terminated or withdrawn. Sponsored by Chinese University of Hong Kong, it has been updated 8 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Feb 2024 — Jul 2024 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Mar 2023 — Feb 2024 [monthly]
Recruiting PHASE3
-
Sep 2021 — Mar 2023 [monthly]
Recruiting PHASE3
▶ Show 3 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Chinese University of Hong Kong
- Janssen, LP
For direct contact, visit the study record on ClinicalTrials.gov .